Labcorp Announces Nationwide Availability Of ColoSense, Its RNA-Based, At-Home Colorectal Cancer Screening Test
- First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas
- Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling
- Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN)
Login to comment